Literature DB >> 25117093

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Katlin Davitt1, Blake D Babcock1, Maly Fenelus2, Chi Kong Poon2, Abhishek Sarkar2, Vincent Trivigno2, Paul A Zolkind2, Sheena M Matthew2, Natalia Grin'kina3, Zulfiya Orynbayeva1, Mohammad F Shaikh1, Victor Adler1, Josef Michl4, Ehsan Sarafraz-Yazdi5, Matthew R Pincus6, Wilbur B Bowne7.   

Abstract

GOALS: We have developed the anti-cancer peptide, PNC-27, which is a membrane-active peptide that binds to the HDM-2 protein expressed in the cancer cell membranes of solid tissue tumor cells and induces transmembrane pore formation in cancer, but not in normal cells, resulting in tumor cell necrosis that is independent of p53 activity in these cells. We now extend our study to non-solid tissue tumor cells, in this case, a primitive, possible stem cell human leukemia cell line (K562) that is also p53-homozygously deleted. Our purpose was twofold: to investigate if these cells likewise express HDM-2 in their plasma membranes and to determine if our anti-cancer peptide induces tumor cell necrosis in these non-solid tissue tumor cells in a manner that depends on the interaction between the peptide and membrane-bound HDM-2. PROCEDURES: The anti-cancer activity and mechanism of PNC-27, which carries a p53 aa12-26-leader sequence connected on its carboxyl terminal end to a trans-membrane-penetrating sequence or membrane residency peptide (MRP), was studied against p53-null K562 leukemia cells. Murine leukocytes were used as a non-cancer cell control. Necrosis was determined by measuring the lactate dehydrogenase (LDH) release and apoptosis was determined by the detection of Caspases 3 and 7. Membrane colocalization of PNC-27 with HDM-2 was analyzed microscopically using fluorescently labeled antibodies against HDM-2 and PNC-27 peptides.
RESULTS: We found that K562 cells strongly express HDM-2 protein in their membranes and that PNC-27 co-localizes with this protein in the membranes of these cells. PNC-27, but not the negative control peptide PNC-29, is selectively cytotoxic to K562 cells, inducing nearly 100 percent cell killing with LDH release. In contrast, this peptide had no effect on the lymphocyte control cells.
CONCLUSIONS: The results suggest that HDM-2 is expressed in the membranes of non-solid tissue tumor cells in addition to the membranes of solid tissue tumor cells. Since K-562 cells appear to be in the stem cell family, the results suggest that early developing tumor cells also express HDM-2 protein in their membranes. Since PNC-27 induces necrosis of K-562 leukemia cells and co-localizes with HDM-2 in the tumor cell membrane as an early event, we conclude that the association of PNC-27 with HDM-2 in the cancer cell membrane results in trans-membrane pore formation which results in cancer cell death, as previously discovered in a number of different solid tissue tumor cells. Since K562 cells lack p53 expression, these effects of PNC-27 on this leukemia cell line occur by a p53-independent pathway.
© 2014 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  PNC-27; apoptosis; cancer; leukemia; necrosis; p53-derived peptide

Mesh:

Substances:

Year:  2014        PMID: 25117093

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  5 in total

1.  Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.

Authors:  Huafeng Wang; Dandan Zhao; Le Xuan Nguyen; Herman Wu; Ling Li; Dan Dong; Estelle Troadec; Yinghui Zhu; Dinh Hoa Hoang; Anthony S Stein; Monzr Al Malki; Ibrahim Aldoss; Allen Lin; Lucy Y Ghoda; Tinisha McDonald; Flavia Pichiorri; Nadia Carlesso; Ya-Huei Kuo; Bin Zhang; Jie Jin; Guido Marcucci
Journal:  Leukemia       Date:  2019-07-23       Impact factor: 11.528

2.  Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.

Authors:  Michal Bassani-Sternberg; Sune Pletscher-Frankild; Lars Juhl Jensen; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2015-01-09       Impact factor: 5.911

Review 3.  Evaluation of the use of therapeutic peptides for cancer treatment.

Authors:  Susan Marqus; Elena Pirogova; Terrence J Piva
Journal:  J Biomed Sci       Date:  2017-03-21       Impact factor: 8.410

4.  Parameters Indicating Development of Influenza-Associated Acute Necrotizing Encephalopathy: Experiences from a Single Center.

Authors:  Suyun Li; Dandan Hu; Peiqing Li; Weiqiang Xiao; Huixian Li; Guangming Liu; Yongling Song; Shuyao Ning; Qiuyan Peng; Danyang Zhao; Minxiong Situ; Wanqi Li; Peiqun Wu; Jipeng Zheng; Yueting Liu; Lin Hu; Pengfei Wang; Zhengbin Hu; Wencheng Ma; Jun Shen; Sida Yang
Journal:  Med Sci Monit       Date:  2021-05-02

5.  Characterization and Molecular Mechanism of Peptide-Conjugated Gold Nanoparticle Inhibiting p53-HDM2 Interaction in Retinoblastoma.

Authors:  Sushma Kalmodia; Sowmya Parameswaran; Kalaivani Ganapathy; Wenrong Yang; Colin J Barrow; Jagat R Kanwar; Kislay Roy; Madavan Vasudevan; Kirti Kulkarni; Sailaja V Elchuri; Subramanian Krishnakumar
Journal:  Mol Ther Nucleic Acids       Date:  2017-10-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.